Kairasec

Candesartan cilexetil, the active ingredient in Kairasec, is a angiotensin II receptor blocker presented as an oral tablet for oral use. It lowers elevated blood pressure and improves outcomes in patients with heart failure. GNH USA supplies Kairasec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kairasec, an angiotensin II receptor blocker, is used to manage conditions related to the renin‑angiotensin system.

Hypertension: reduces systolic and diastolic blood pressure, decreasing cardiovascular risk. Heart failure: improves functional capacity and reduces hospitalisation rates by decreasing afterload and neurohormonal activation. Post‑myocardial infarction (off‑label in some regions): may aid in ventricular remodeling prevention, though use depends on local guidelines.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Upper respiratory tract infection symptoms - Diarrhoea - Nasal congestion

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Hyperkalaemia (elevated blood potassium) - Acute renal impairment - Hepatic injury - Severe hypotension - Myocardial infarction or worsening heart failure

Before starting Kairasec, clinicians should consider several safety measures. - Monitor blood pressure: ensure adequate control and avoid hypotension. - Assess renal function: check serum creatinine and eGFR periodically. - Check serum potassium: avoid hyperkalaemia, especially with potassium‑sparing agents. - Contraindicated in pregnancy: category D, discontinue if pregnancy is confirmed. - Use caution in elderly patients: start at lower doses and monitor for orthostatic effects. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Kairasec may interact with several medicines that affect the renin‑angiotensin‑aldosterone system or electrolyte balance.

Major Interactions (Avoid): - Aliskiren in patients with diabetes or renal impairment - Dual therapy with ACE inhibitors or other ARBs - Potassium‑sparing diuretics (e.g., spironolactone) leading to hyperkalaemia

Moderate Interactions (Monitor Closely): - Conventional diuretics (thiazides) may increase hypotensive effect - Lithium: candesartan can raise lithium levels - NSAIDs: may reduce antihypertensive efficacy and affect renal function - Rifampin: may lower candesartan plasma concentrations